High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
- PMID: 24935963
- PMCID: PMC4112445
- DOI: 10.1136/jmedgenet-2014-102320
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
Abstract
Background: Germline mutations in the tumour suppressor gene CDKN2A occur in 5-20% of familial melanoma cases. A single founder mutation, p.Arg112dup, accounts for the majority of CDKN2A mutations in Swedish carriers. In a national program, carriers of p.Arg112dup mutation have been identified. The aim of this study was to assess cancer risks in p.Arg112dup carriers and their first degree relatives (FDRs) and second degree relatives (SDRs).
Methods: In this prospective cohort study, cancer diagnoses in carriers (n=120), non-carriers (n=111), carriers' FDRs (n=275) and SDRs (n=321) and controls (n=3976) were obtained from the Swedish Cancer Registry. Relative risks (RRs) for cancers were calculated (number of cancers/person years). Two-sided 95% CIs were calculated for all RRs.
Results: In carriers prospective RR for non-melanoma cancers was 5.0 (95% CI 3.7 to 7.3), for pancreatic cancer 43.8 (95% CI 13.8 to 139.0), for cancers in upper digestive tissues 17.1 (95% CI 6.3 to 46.5), and in respiratory tissues 15.6 (5.4 to 46.0). In FDRs and SDRs RRs were significantly elevated for cancers in pancreas, respiratory and upper digestive tissues. In ever-smoking carriers compared with never-smoking carriers, the odds ratio (OR) of cancers in pancreas, respiratory or upper digestive tissues was 9.3 (95% CI 1.9 to 44.7).
Conclusions: CDKN2A p.Arg112dup mutation carriers from melanoma-prone families and their FDRs and SDRs have elevated risk for pancreatic, lung, head and neck and gastro-oesophageal carcinomas. These cancers were mainly seen in ever-smoking carriers. Germline CDKN2A mutations may confer an increased sensitivity to carcinogens in tobacco smoke. CDKN2A mutation carriers should be counselled to abstain from smoking.
Keywords: Cancer: dermatological; Cancer: head and neck; Cancer: lung; Genetic epidemiology; Genetic screening/counselling.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
Similar articles
-
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.J Natl Cancer Inst. 2012 Jun 20;104(12):953-6. doi: 10.1093/jnci/djs221. Epub 2012 Apr 24. J Natl Cancer Inst. 2012. PMID: 22534780 Free PMC article.
-
CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.Int J Cancer. 2015 Nov 1;137(9):2220-6. doi: 10.1002/ijc.29595. Epub 2015 May 21. Int J Cancer. 2015. PMID: 25943250
-
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.Eur J Hum Genet. 2011 Apr;19(4):472-8. doi: 10.1038/ejhg.2010.198. Epub 2010 Dec 8. Eur J Hum Genet. 2011. PMID: 21150883 Free PMC article.
-
MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.Eur J Cancer. 2010 May;46(8):1413-20. doi: 10.1016/j.ejca.2010.01.027. Epub 2010 Feb 26. Eur J Cancer. 2010. PMID: 20189796 Review.
-
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.Biomolecules. 2020 Oct 15;10(10):1447. doi: 10.3390/biom10101447. Biomolecules. 2020. PMID: 33076392 Free PMC article. Review.
Cited by
-
Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145. JCO Precis Oncol. 2022. PMID: 36409970 Free PMC article.
-
Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.Front Oncol. 2022 Mar 16;12:837057. doi: 10.3389/fonc.2022.837057. eCollection 2022. Front Oncol. 2022. PMID: 35372037 Free PMC article. Review.
-
Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.J Eur Acad Dermatol Venereol. 2023 Feb;37(2):284-292. doi: 10.1111/jdv.18589. Epub 2022 Oct 1. J Eur Acad Dermatol Venereol. 2023. PMID: 36156317 Free PMC article.
-
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.
-
Genome-wide linkage analysis in Spanish melanoma-prone families identifies a new familial melanoma susceptibility locus at 11q.Eur J Hum Genet. 2018 Aug;26(8):1188-1193. doi: 10.1038/s41431-018-0149-8. Epub 2018 Apr 30. Eur J Hum Genet. 2018. PMID: 29706638 Free PMC article.
References
-
- Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. New York: Grune & Stratton, 1979
-
- Skolnick MH, Cannon-Albright LA, Kamb A. Genetic predisposition to melanoma. Eur J Cancer 1994;30A:1991–5 - PubMed
-
- Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in u.S. Melanoma-prone families with cdkn2a and cdk4 mutations . J Natl Cancer Inst 2000;92:1006–10 - PubMed
-
- Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in cdkn2a mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260–6 - PubMed
-
- Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. Screening of germline mutations in the cdkn2a and cdkn2b genes in swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697–702 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous